Why the study?
Myocardial no-reflow after PPCI for STEMI is associated with worse outcomes, prompting investigation into whether admission inflammatory and lipid markers and ratios relate to its development.
Do admission CRP/Albumin ratio and Monocytes/HDL ratio predict angiographic no-reflow in patients with STEMI undergoing primary PCI?
Do admission CRP/Albumin ratio and Monocytes/HDL ratio predict angiographic no-reflow in patients with STEMI undergoing primary PCI?
Admission CRP/Albumin ratio and Monocytes/HDL ratio are easily measurable, independent predictors of angiographic no-reflow in STEMI patients undergoing primary PCI.
Answers are grounded in this paper and cite their sources.
May support no-reflow risk stratification in STEMI; hypothesis-generating and should not yet change practice without prospective validation.
Background Primary Percutaneous coronary intervention (PPCI) is an established mainstay in treatment of patients presenting with acute ST elevation myocardial infarction (STEMI). However, successful revascularization of the culprit coronary vessel does not always mean ideal myocardial reperfusion in a portion of patients, mainly because of the no-reflow phenomenon. Myocardial no-reflow is associated with worse contractile dysfunction and higher incidence of complications and is an independent predictor of death and myocardial infarction after PPCI. Objective: To study the relationship between admissions CRP, Albumin, CRP/Albumin ratio, Monocyte, HDL, and Monocyte/HDL ratio, in patients presenting with acute STEMI and angiographic no-reflow after PPCI. Material and Methods: From October 2018 to February 2019, of the 1500 patients who presented with STEMI for PPCI to any of the Ain Shams University Hospitals’ cath labs, we enrolled 150 consecutive patients who had post revascularization angiographic no-reflow. They were allocated to group A. we allocated 150 age, gender, and baseline characteristics matched STEMI patients who had TIMI III flow post revascularization to group B. this was set as the control group. Results: The study population was divided into 2 groups: no-reflow “A” (n = 150) and reflow “B” (n = 150) groups. CRP and Monocytes were significantly higher in the no-reflow group; Albumin and HDL were significantly lower in the no-reflow group. The novel indices, CRP/Albumin ratio (CAR) and Monocytes/HDL ratio (MHR) were both significantly higher in the no-reflow group (p value = 0.000) for both. The tow indices were found to be independent predictors of no-reflow development. Conclusion: Our results suggested that CAR and MHR on admission before PPCI though cheap, and easily measurable laboratory tools, have a significant predictive value with an odds ratio of 0.182 with a p value = 0.000 and 0.321 with a p value = 0.002 respectively. They could help to risk stratify STEMI patients who might suffer from no-reflow phenomenon after PPCI.
No takes yet. Share an insight, caveat, or question.
Khaled Mohamed Said Othman (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: